文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

慢性阻塞性肺疾病患者使用压力定量吸入器:证据综述

Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence.

作者信息

Aggarwal Bhumika, Gogtay Jaideep

机构信息

Medical Services, Cipla Ltd, Mumbai, India.

出版信息

Expert Rev Respir Med. 2014 Jun;8(3):349-56. doi: 10.1586/17476348.2014.905916. Epub 2014 May 7.


DOI:10.1586/17476348.2014.905916
PMID:24802511
Abstract

The inhaled route is considered to be the best route to administer drugs for treating respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), for both safety and efficacy. Inhalation devices are classified into four types - pressuriszed metered dose inhalers (pMDIs), dry powder inhalers, breath actuated inhalers and nebulizers. pMDIs are portable, convenient, multi-dose devices and these advantages have made them very popular with patients. They were introduced in the 1950s as the first portable, multi-dose delivery system for bronchodilators. Even though pMDIs are the most widely used devices for inhalation therapy in asthma and COPD, studies establishing their use and providing clinical data with bronchodilators and combination therapies in patients with COPD are limited. A summary of the use of pMDI with spacers in patients with COPD in terms of lung deposition and impact on lung function are presented in this review article. A review of use of the pMDI device in patients with COPD with different available and prescribed medications (bronchodilators-β2-agonists and anticholinergics, and their combination with inhaled corticosteroids) is discussed.

摘要

从安全性和有效性两方面考虑,吸入途径被认为是治疗哮喘和慢性阻塞性肺疾病(COPD)等呼吸道疾病给药的最佳途径。吸入装置分为四类——压力定量吸入器(pMDIs)、干粉吸入器、呼吸驱动吸入器和雾化器。pMDIs是便携式、方便的多剂量装置,这些优点使其在患者中非常受欢迎。它们于20世纪50年代作为第一种用于支气管扩张剂的便携式多剂量给药系统被引入。尽管pMDIs是哮喘和COPD吸入治疗中使用最广泛的装置,但关于其在COPD患者中使用并提供支气管扩张剂和联合疗法临床数据的研究有限。本文综述了pMDI加储雾罐在COPD患者中的使用情况,包括肺沉积及对肺功能的影响。还讨论了pMDI装置在使用不同可用和处方药物(支气管扩张剂——β2激动剂和抗胆碱能药物,以及它们与吸入性糖皮质激素的联合使用)的COPD患者中的应用。

相似文献

[1]
Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence.

Expert Rev Respir Med. 2014-6

[2]
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.

Health Technol Assess. 2001

[3]
Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide.

Respir Med. 2005-7

[4]
Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.

Respir Med. 2007-12

[5]
Inhalatory therapy training: a priority challenge for the physician.

Acta Biomed. 2007-12

[6]
The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.

Int J Chron Obstruct Pulmon Dis. 2015-10-29

[7]
Inhaler devices for patients with COPD.

COPD. 2013-3-28

[8]
A narrative review on the Synchrobreathe™: A novel breath-actuated pressurised metered-dose inhaler for the treatment of obstructive airway diseases.

Respir Med. 2023

[9]
Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD.

J Clin Pharmacol. 2008-11

[10]
Clinical equivalence of budesonide dry powder inhaler and pressurized metered dose inhaler.

Clin Respir J. 2016-1

引用本文的文献

[1]
Safety of budesonide/glycopyrronium/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study.

EClinicalMedicine. 2025-8-12

[2]
Inhalable Nanotechnology-Based Drug Delivery Systems for the Treatment of Inflammatory Lung Diseases.

Pharmaceutics. 2025-7-9

[3]
Pulmonary inhalation for disease treatment: Basic research and clinical translations.

Mater Today Bio. 2024-1-22

[4]
Errors in Aerosol Inhaler Use and Their Effects on Maternal and Fetal Outcomes among Pregnant Asthmatic Women (Subanalysis from QAKCOP Study).

Can Respir J. 2018-12-18

[5]
Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.

NPJ Prim Care Respir Med. 2016-6-16

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索